The UK Medicines and Health Products Regulatory Authority (MHRA) reported that Moderna productcontaining 25 micrograms of vaccine that works against the original version and 25 micrograms of the vaccine developed for the Omikron variant, meets the standards of safety, quality and effectiveness.
A two-variant vaccine will be available in the fall as a booster dose. The Joint Committee on Vaccination and Immunization (JCVI) will decide who will be eligible. From September, all high-risk people over 50 and younger will be able to receive some form of booster vaccination.
The vaccines used during the Covid-19 pandemic are designed to help the body fight the primary form of the virus that emerged in Wuhan, China in late 2019. Since then, the coronavirus has significantly mutated, resulting in a number of new variants, of which some are more resistant to vaccines. They have caused large spikes in cases around the world.
See also: Coronavirus is haunting Europe again. How will the seventh wave hit the Polish economy?
The rest of the article is below the video
Results of tests carried out on 437 people showed that people who received the new version of the vaccine had levels of antibodies that could inactivate the original Omikron variant (BA.1), as well as its later sub-variants (BA.4 and BA.5), which the current wave of cases in the UK.
Moderna has submitted a two-variant vaccine for approval also to regulators in the European Union, Australia and Canada. It is expected to be approved by the EU by September.